全文获取类型
收费全文 | 11106篇 |
免费 | 686篇 |
国内免费 | 100篇 |
专业分类
耳鼻咽喉 | 104篇 |
儿科学 | 221篇 |
妇产科学 | 308篇 |
基础医学 | 1442篇 |
口腔科学 | 444篇 |
临床医学 | 915篇 |
内科学 | 2738篇 |
皮肤病学 | 136篇 |
神经病学 | 962篇 |
特种医学 | 455篇 |
外科学 | 1880篇 |
综合类 | 33篇 |
预防医学 | 445篇 |
眼科学 | 116篇 |
药学 | 676篇 |
中国医学 | 31篇 |
肿瘤学 | 986篇 |
出版年
2023年 | 79篇 |
2022年 | 103篇 |
2021年 | 320篇 |
2020年 | 223篇 |
2019年 | 326篇 |
2018年 | 400篇 |
2017年 | 272篇 |
2016年 | 329篇 |
2015年 | 390篇 |
2014年 | 592篇 |
2013年 | 649篇 |
2012年 | 957篇 |
2011年 | 966篇 |
2010年 | 523篇 |
2009年 | 499篇 |
2008年 | 765篇 |
2007年 | 782篇 |
2006年 | 651篇 |
2005年 | 650篇 |
2004年 | 644篇 |
2003年 | 514篇 |
2002年 | 416篇 |
2001年 | 66篇 |
2000年 | 56篇 |
1999年 | 70篇 |
1998年 | 61篇 |
1997年 | 63篇 |
1996年 | 46篇 |
1995年 | 52篇 |
1994年 | 59篇 |
1993年 | 51篇 |
1992年 | 35篇 |
1991年 | 42篇 |
1990年 | 29篇 |
1989年 | 30篇 |
1988年 | 27篇 |
1987年 | 20篇 |
1986年 | 20篇 |
1985年 | 14篇 |
1984年 | 17篇 |
1983年 | 12篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1975年 | 6篇 |
1974年 | 6篇 |
1973年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Davide Fiore Bavaro Flavia Balena Luigi Ronga Fabio Signorile Federica Romanelli Stefania Stolfa Eleonora Sparapano Carmela De Carlo Adriana Mosca Laura Monno Gioacchino Angarano Annalisa Saracino 《Journal de Mycologie Médicale》2022,32(1):101206
An increased number of patients is at risk of Candida spp. bloodstream infection (CBSI) in modern medicine. Moreover, the rising of antifungal resistance (AR) was recently reported. All consecutive CBSI occurred in our Hospital (consisting of 1,370 beds) between 2015 and 2018, were reviewed. For each case, Candida species, AR pattern, ward involved and demographic data of patients were recorded. Overall, 304 episodes of CBSI occurred, with a median (q1:first-,q3:third quartile) of 77 (71-82) CBSI/year. Over the years, a significant increase of CBSI due to C. albicans compared to non-albicans strains was recorded in medical wards (from 65% to 71%, p=0.030), while this ratio remained stable in others. An increase of resistant strains to multiple antifungals such as C. guillermondii was noticed in recent years (from 0% to 9.8%, p=0.008). Additionally, from 2015 to 2018 an increase in fluconazole-resistance was recorded in our Hospital (from 7.4% to 17.4%, p=0.025) and a slight increase in voriconazole-resistance (from 0% to 7% in 2018, p=0.161) was observed, while resistance to echinocandin and amphotericin B remained firmly below 2%.This study suggests a rapid spread of antifungal resistance in our Hospital; therefore, an appropriate antifungal stewardship programs is urgently warranted. 相似文献
2.
Traboulsi-Garet Bassel Jorba-García Adrià Camps-Font Octavi Alves Fabio Abreu Figueiredo Rui Valmaseda-Castellón Eduard 《Clinical oral investigations》2022,26(3):2371-2382
Clinical Oral Investigations - To determine the usefulness of Serum C-terminal telopeptide cross-link of type 1 collagen (sCTX) as a preoperative marker for predicting the risk of developing... 相似文献
3.
4.
5.
6.
7.
Fabio Gaetano Santeramo Marco Tappi Emilia Lamonaca 《Health policy (Amsterdam, Netherlands)》2021,125(8):995-1001
The fast-moving coronavirus disease 2019 (COVID-19) called for a rapid response to slowing down the viral spread and reduce the fatality associated to the pandemic. Policymakers have implemented a wide range of non-pharmaceutical interventions to mitigate the spread of the pandemic and reduce burdens on healthcare systems. An efficient response of healthcare systems is crucial to handle a health crisis. Understanding how non-pharmaceutical interventions have contributed to slowing down contagions and how healthcare systems have impacted on fatality associated with health crisis is of utmost importance to learn from the COVID-19 pandemic. We investigated these dynamics in Italy at the regional level. We found that the simultaneous introduction of a variety of measures to increase social distance is associated with an important decrease in the number of new infected patients detected daily. Contagion reduces by 1% with the introduction of lockdowns in an increasing number of regions. We also found that a robust healthcare system is crucial for containing fatality associated with COVID-19. Also, proper diagnosis strategies are determinant to mitigate the severity of the health outcomes. The preparedness is the only way to successfully adopt efficient measures in response of unexpected emerging pandemics. 相似文献
8.
Licia Iaccarino Tiziana Ottone Valentina Alfonso Laura Cicconi Mariadomenica Divona Serena Lavorgna Serena Travaglini Aleandra Ferrantini Giulia Falconi Constance Baer Monica Usai Fabio Forghieri Adriano Venditti Maria Ilaria Del Principe William Arcese Maria Teresa Voso Torsten Haferlach Francesco Lo-Coco 《American journal of hematology》2019,94(10):1091-1097
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile. 相似文献
9.
Robert J. Motzer MD Bernard Escudier MD Saby George MD Hans J. Hammers MD PhD Sandhya Srinivas MD Scott S. Tykodi MD PhD Jeffrey A. Sosman MD Elizabeth R. Plimack MD Giuseppe Procopio MD David F. McDermott MD Daniel Castellano MD Toni K. Choueiri MD Frede Donskov MD PhD Howard Gurney MD Stéphane Oudard MD Martin Richardet MD PhD Katriina Peltola MD PhD Ajjai S. Alva MD Michael Carducci MD John Wagstaff MD Christine Chevreau MD Satoshi Fukasawa MD Yoshihiko Tomita MD PhD Thomas C. Gauler MD Christian K. Kollmannsberger MD Fabio A. Schutz PhD James Larkin MD PhD David Cella PhD M. Brent McHenry PhD Shruti Shally Saggi BEng Nizar M. Tannir MD 《Cancer》2020,126(18):4156-4167
10.
Matteo Lambertini Francesca Poggio Marco Bruzzone Benedetta Conte Claudia Bighin Evandro de Azambuja Mario Giuliano Michele De Laurentiis Francesco Cognetti Alessandra Fabi Giancarlo Bisagni Antonio Durando Anna Turletti Ylenia Urracci Ornella Garrone Fabio Puglisi Filippo Montemurro Marcello Ceppi Lucia Del Mastro the GIM investigators 《International journal of cancer. Journal international du cancer》2020,147(1):160-169
Dose-dense adjuvant chemotherapy is standard of care in high-risk early breast cancer patients. However, its role in HER2-positive patients is still uncertain. In this exploratory analysis of the GIM2 trial, we investigated the efficacy of dose-dense chemotherapy in HER2-positive breast cancer patients with or without exposure to trastuzumab. In the GIM2 trial, node-positive early breast cancer patients were randomized to receive four cycles of (fluorouracil)epirubicin/cyclophosphamide followed by four cycles of paclitaxel administered every 2 (dose-dense) or 3 (standard-interval) weeks. After approval of adjuvant trastuzumab, protocol was amended in April 2006 to allow use of trastuzumab for 1 year after chemotherapy completion in HER2-positive patients. The efficacy of dose-dense chemotherapy in terms of disease-free survival (DFS) and overall survival (OS) was assessed according to HER2 status and trastuzumab use. Out of 2,003 breast cancer patients, HER2 status was negative/unknown in 1,551 patients; among the 452 patients with HER2-positive breast cancer, chemotherapy alone or followed by trastuzumab was given to 320 and 132 patients, respectively. Median follow-up was 8.1 years. No significant interaction between HER2 status, trastuzumab use and chemotherapy treatment was observed for both DFS (p = 0.698) and OS (p = 0.708). Nevertheless, there was no apparent benefit in the HER2-positive group treated with trastuzumab (DFS: HR, 0.99; 95% CI 0.52–1.89; OS: HR, 0.95; 95% CI 0.37–2.41). Although dose-dense chemotherapy was associated with a significant survival improvement in high-risk breast cancer patients, its benefit appeared to be smaller (if any) in patients with HER2-positive disease who received adjuvant trastuzumab. 相似文献